SAMD9L acts as an antiviral factor against HIV-1 and primate lentiviruses by restricting viral and cellular translation.


Journal

PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 15 04 2024
accepted: 31 05 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 3 7 2024
Statut: epublish

Résumé

Sterile alpha motif domain-containing proteins 9 and 9-like (SAMD9/9L) are associated with life-threatening genetic diseases in humans and are restriction factors of poxviruses. Yet, their cellular function and the extent of their antiviral role are poorly known. Here, we found that interferon-stimulated human SAMD9L restricts HIV-1 in the late phases of replication, at the posttranscriptional and prematuration steps, impacting viral translation and, possibly, endosomal trafficking. Surprisingly, the paralog SAMD9 exerted an opposite effect, enhancing HIV-1. More broadly, we showed that SAMD9L restricts primate lentiviruses, but not a gammaretrovirus (MLV), nor 2 RNA viruses (arenavirus MOPV and rhabdovirus VSV). Using structural modeling and mutagenesis of SAMD9L, we identified a conserved Schlafen-like active site necessary for HIV-1 restriction by human and a rodent SAMD9L. By testing a gain-of-function constitutively active variant from patients with SAMD9L-associated autoinflammatory disease, we determined that SAMD9L pathogenic functions also depend on the Schlafen-like active site. Finally, we found that the constitutively active SAMD9L strongly inhibited HIV, MLV, and, to a lesser extent, MOPV. This suggests that the virus-specific effect of SAMD9L may involve its differential activation/sensing and the virus ability to evade from SAMD9L restriction. Overall, our study identifies SAMD9L as an HIV-1 antiviral factor from the cell autonomous immunity and deciphers host determinants underlying the translational repression. This provides novel links and therapeutic avenues against viral infections and genetic diseases.

Identifiants

pubmed: 38959200
doi: 10.1371/journal.pbio.3002696
pii: PBIOLOGY-D-24-01135
doi:

Substances chimiques

SAMD9L protein, human 0
SAMD9 protein, human 0
Antiviral Restriction Factors 0
Intracellular Signaling Peptides and Proteins 0
Tumor Suppressor Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3002696

Informations de copyright

Copyright: © 2024 Legrand et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Alexandre Legrand (A)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Clara Dahoui (C)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Clément De La Myre Mory (C)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Kodie Noy (K)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.
Unité de Biologie des Infections Virales Émergentes, Institut Pasteur, Lyon, Université Paris Cité, Paris, France.

Laura Guiguettaz (L)

Laboratoire de Biologie et Modélisation de la Cellule (LBMC), Université de Lyon, INSERM U1293, CNRS UMR 5239, ENS de Lyon, UCBL1, Lyon, France.

Margaux Versapuech (M)

Université Paris Cité, CNRS, Inserm, Institut Cochin, INSERM, CNRS, Paris, France.

Clara Loyer (C)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Margaux Pillon (M)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Mégane Wcislo (M)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Laurent Guéguen (L)

Laboratoire de Biologie et Biométrie Évolutive (LBBE), CNRS UMR 5558, UCBL1, Villeurbanne, France.

Clarisse Berlioz-Torrent (C)

Université Paris Cité, CNRS, Inserm, Institut Cochin, INSERM, CNRS, Paris, France.

Andrea Cimarelli (A)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Mathieu Mateo (M)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.
Unité de Biologie des Infections Virales Émergentes, Institut Pasteur, Lyon, Université Paris Cité, Paris, France.

Francesca Fiorini (F)

Retroviruses and structural biochemistry, Molecular Microbiology and Structural Biochemistry (MMSB), IBCP, CNRS UMR 5086, University of Lyon, Lyon, France.

Emiliano P Ricci (EP)

Laboratoire de Biologie et Modélisation de la Cellule (LBMC), Université de Lyon, INSERM U1293, CNRS UMR 5239, ENS de Lyon, UCBL1, Lyon, France.

Lucie Etienne (L)

Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, UCBL1, CNRS UMR 5308, ENS de Lyon, Université de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH